â??Comparison of the Efficacy and Safety of High Dose Monotherapy and Low Dose Combination of Telmisartan and/or Amlodipine in Inadequately Controlled Hypertensive Patients taking Low Dose Monotherapy of Either Drug- A Single Center, Open Label, Three-Arm, Randomized, Parallel Group, Prospective Study.â??

Self0 个研究点目标入组 90 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Hypertensive patients with uncontrolled blood pressure (Systolic BP >= 140 to 179 mmHg and/or Diastolic BP >= 90 to 109 mmHg) on low dose monotherapy with either Amlodipine (<= 5mg) or Telmisartan (<= 40 mg).
•2 Age 18 to 60 years, either gender.
•3 Patients who are willing to participate and sign consent document.
•4 Patient willing to comply with the protocol requirements.

•1 Secondary Hypertension.
•2 Clinically evident concomitant disorder such as cardiovascular, renal, hepatic, endocrine, neurological, psychiatric or other complicating diseases or severe co-morbidities.
•3 Pregnant or lactating women.
•4 Female patients of childbearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study period.
•5 Patients with known hypersensitivity to any of the test drug.
•6 Patients with alcohol or drug dependence.
•7 Patients with stage 3 hypertension (Systolic BP >= 180 mmHg and/or Diastolic BP >= 110 mmHg)
•8 Patients who had any major surgery within 4 weeks of screening.
•9 Any other condition that in the opinion of the Investigator that does not justify the patientâ??s participation in the study.

发起方